Hepion Pharmaceuticals, Inc. has filed an amended Schedule 13G with the SEC, detailing changes in beneficial ownership. This filing, dated October 21, 2026, is significant as it reflects the company's ongoing efforts to manage its shareholder landscape and align with strategic interests.

Background

Hepion Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is traded on the OTC exchange under the tickers HEPA and CTRVP. Recent filings include various forms, such as a Schedule 13D on October 26, 2026, and a Form 3 on the same day as the Schedule 13G/A.

What the Filing Says

The filing indicates an amendment to previous disclosures regarding beneficial ownership. However, specific details about the changes were not available in the SEC filing.

Impact

This update may affect current and potential investors, as well as stakeholders within the pharmaceutical preparations industry. Changes in ownership can signal shifts in company strategy and investor confidence.

What's Next

The filing does not say what happens next.

Company Information

Hepion Pharmaceuticals, Inc. is incorporated in Delaware and operates under the Employer Identification Number (EIN) 462783806. The company’s fiscal year ends on December 31. The filing also provides information about the company's classification under the Standard Industrial Code (SIC) 2834, which pertains to pharmaceutical preparations.

Filing Details

The amended Schedule 13G/A was accepted by the SEC on the same day it was filed, October 21, 2026, at 16:57:29. This filing is categorized under Act 34 and has a file number of 005-87637.

Contact Information

Hepion Pharmaceuticals is located at 34 Shrewsbury Ave., Suite 1D, Red Bank, NJ 07701. The company can be reached at the phone number 732-902-4000.

Additional Context

The filing does not provide specific details about the changes in beneficial ownership or the identities of the investors involved. Furthermore, it does not indicate any implications or strategic moves that may follow this amendment.